Last checked at 19 May 2020 14:29
19 May 2020
Diaceutics PLC
("Diaceutics" or the "Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.
Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:
Resolution | For &Discretionary | Against | Withheld | Total votes cast | |||
Number of votes | % | Number of votes | % | Number of votes | |||
1 | Ordinary resolution to receive and consider the 2019 Financial Statements | 50,023,247 | 100.00% | 0 | 0.00% | 0 | 50,023,247 |
2 | Ordinary resolution to re-elect Julie Goonewardene as a director | 49,984,878 | 99.92% | 38,369 | 0.08% | 0 | 50,023,247 |
3 | Ordinary resolution to re-elect Charles Hindson as a director | 49,969,009 | 100.00% | 0 | 0.00% | 54,238 | 49,969,009 |
4 | Ordinary resolution to re-elect Mike Wort as a director | 49,969,009 | 100.00% | 0 | 0.00% | 54,238 | 49,969,009 |
5 | Ordinary resolution to re-elect Peter Keeling as a director | 50,023,247 | 100.00% | 0 | 0.00% | 0 | 50,023,247 |
6 | Ordinary resolution to re-elect Ryan Keeling as a director | 49,984,878 | 99.92% | 38,369 | 0.08% | 0 | 50,023,247 |
7 | Ordinary resolution to re-elect Philip White as a director | 50,023,247 | 100.00% | 0 | 0.00% | 0 | 50,023,247 |
8 | Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors | 49,984,878 | 100.00% | 0 | 0.00% | 38,369 | 49,984,878 |
9 | Ordinary resolution to authorise the directors to determine the remuneration of the auditors | 50,007,378 | 100.00% | 0 | 0.00% | 15,869 | 50,007,378 |
10 | Ordinary resolution to authorise the directors to allot shares | 49,984,878 | 99.92% | 38,369 | 0.08% | 0 | 50,023,247 |
11 | Special resolution to authorise the directors to disapply pre-emption rights | 49,983,480 | 99.92% | 39,767 | 0.08% | 0 | 50,023,247 |
12 | Special resolution to authorise the directors to purchase own shares | 47,744,794 | 99.92% | 39,453 | 0.08% | 2,239,000 | 47,784,247 |
Enquiries
Diaceutics PLC |
|
Stuart Hunt, Head of Investor Relations | Tel: +44 (0)7815 778 536 |
|
|
Cenkos Securities PLC (Nomad & Broker) | Tel: +44(0)20 7397 8900 |
Callum Davidson / Giles Balleny |
|
Michael Johnson (Sales) |
|
|
|
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com |
Anna Dunphy | Tel: +44 (0)7876 741 001 |
Paul McManus | Tel: +44 (0)7980 541 893 |
About Diaceutics
Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com